Thiogenesis Expands European Reach with New Consultancy Agreement

An announcement from Thiogenesis Therapeutics Corp ( (TSE:TTI) ) is now available.

Thiogenesis Therapeutics Corp. has entered into a consulting and investor relations agreement with Bull Markets Media GmbH to expand its shareholder base and network in Europe. The agreement involves a consultancy fee and stock options, with the possibility of annual renewal for two additional years, subject to TSX Venture Exchange approval. This strategic move is expected to enhance Thiogenesis’s market presence in Europe, potentially impacting its operations and stakeholder engagement positively.

More about Thiogenesis Therapeutics Corp

Thiogenesis Therapeutics, Corp. is a clinical-stage biopharmaceutical company based in San Diego, focused on developing sulfur-containing prodrugs that become active only upon metabolism. These prodrugs aim to treat serious pediatric diseases with unmet medical needs, leveraging streamlined regulatory pathways to enhance drug bioavailability and reduce side effects. Target indications include MELAS, Leigh syndrome, Rett syndrome, and pediatric MASH.

YTD Price Performance: 10.0%

Average Trading Volume: 20,167

Technical Sentiment Consensus Rating: Sell

Current Market Cap: C$29.08M

Learn more about TTI stock on TipRanks’ Stock Analysis page.